Dimension Therapeutics

46 articles about Dimension Therapeutics

• Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics

  11/7/2017

  Ultragenyx purchased all outstanding shares of common stock of Dimension for $6.00 per share in cash, without interest, or approximately $152.3 million in cash.

• 

  Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx's...

  10/26/2017

  Ultragenyx and Dimension struck the m&a deal on October 2, 2017,

• Ultragenyx To Acquire Dimension Therapeutics

  10/3/2017

• REGENXBIO Officially Backs Out Of Dimension Therapeutics Deal, Gets $2.85 Million Break Up Fee

  10/3/2017

• Ultragenyx Comments On Dimension Therapeutics’ Announcement That Ultragenyx’s Offer Is A “Superior Proposal”

  10/2/2017

• REGENXBIO Responds To Notification Of A Superior Proposal Under Its Merger Agreement With Dimension Therapeutics

  10/2/2017

• Dimension Therapeutics Board Of Directors Determines Proposal From Ultragenyx Could Reasonably Be Expected To Lead To A “Superior Proposal”

  9/19/2017

• Bay Area's Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics

  9/19/2017

• Dimension Therapeutics Commences Patient Dosing In Global, Multi-Center Phase I/II Clinical Trial Of DTX301 In Ornithine Transcarbamylase (OTC) Deficiency

  8/31/2017

• Troubled Dimension Therapeutics Sold in All-Stock Deal

  8/25/2017

• REGENXBIO To Acquire Dimension Therapeutics

  8/25/2017

• Dimension Therapeutics Reports Second Quarter 2017 Financial Results And Provides Corporate Update

  8/8/2017

• Dimension Therapeutics Announces Management Change

  7/24/2017

• Dimension Therapeutics Pink Slips 25% of Workforce

  6/28/2017

• Dimension Therapeutics Throws In The Towel On Hemophilia B Drug

  5/10/2017

• Cambridge's Dimension Therapeutics Tanks to a New Low After Revealing Interim Hemophilia B Data

  2/1/2017

• Aptuit LLC And Dimension Therapeutics Enter Strategic Partnership To Advance Select Dimension Programs Toward IND Filing

  7/7/2016

• 3 Biotech Stocks Flying High Under-the-Radar

  5/27/2016

• Dimension Therapeutics Announces Preclinical Data From Bayer-Partnered Hemophilia A Program At American Society For Gene And Cell Therapy (ASGCT) Annual Meeting

  5/9/2016

• Like Dimension Therapeutics, More Than Half of Yumanity's Employees are Women

  2/12/2016